Gas synergistic sonodynamic modified albumin drug nanoparticles, and preparation method and application thereof

Abstract

The invention discloses a gas synergistic sonodynamic modified albumin drug nanoparticle and a preparation method and application thereof. The nanoparticle comprises a modified albumin molecule, a sound-sensitive agent and a chemical crosslinking molecule, and modified albumin molecules are used as a nanoparticle skeleton, small molecules containing azo groups are used as a chemical cross-linking agent, and a sound-sensitive agent is coated. The modified albumin has a donor structure capable of effectively performing ultrasonic excitation to release NO, NO reacts with superoxide anions to form peroxynitrite, protein functions can be changed, DNA can be damaged, and the modified albumin is helpful to cooperate with a sound-sensitive agent to kill tumor cells and intracellular pathogens; and through the chemical cross-linking agent with the azo group, the azo bond can be broken under the ultrasonic action to generate free radicals, so that the nanoparticles are damaged to release the entrapped medicine, and the release amount of the medicine is related to the ultrasonic time and intensity, so that the purpose of controllable medicine release is achieved.

Description

technical field [0001] The invention belongs to the field of biomedical new materials, and in particular relates to a gas synergistic sonodynamically modified albumin drug nanoparticle, a preparation method thereof, and an application of the drug release through ultrasonic action. Background technique [0002] Albumin is the most abundant serum protein in the blood. It is often selected as a drug carrier due to its high water solubility, good stability, and high biocompatibility. There are a large number of amino acid residues in the primary structure of albumin, which is Several small molecules (ligands) provide binding sites and are capable of payloads for many different classes of drugs. As the carrier of drug delivery, human serum albumin (HSA) and bovine serum albumin (BSA) are the most studied. HAS is a soluble single-chain globular protein with a molecular weight of 67kDa and composed of 585 amino acids. HAS has many drug binding sites and can bind to salicylic acid,...

AI Technical Summary

Problems solved by technology

[0004] In short, the existing technology has the problem that albumin nanoparticles cannot controlly release drugs under physiological conditions, and can only release drugs slowly under endogenous stimuli such as acidity or reduction, while light-controlled release has poor tissue penetration, resulting in Defects such as low drug release need to be solved urgently

[0005] Chinese invention patent (application) CN202010186222.2 discloses an albumin nanoparticle that can be activated by ultrasound to release drugs, its preparation method and application. It uses an azo cross-linking agent and carries a chemotherapeutic drug for ultrasound release, but the patent uses Albumin is unmodified albumin, without considering the modification of albumin, it does not involve the release of NO signal molecules, does not involve the entrapment of sound sensitizer drugs, and cannot achieve the therapeutic effect of gas synergy with sonodynamics

Images